Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases. - Inserm - Institut national de la santé et de la recherche médicale Access content directly
Journal Articles Journal of Hematology and Oncology Year : 2012

Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases.

Abstract

ABSTRACT: The ASXL1 gene is one of the most frequently mutated genes in malignant myeloid diseases. The ASXL1 protein belongs to protein complexes involved in the epigenetic regulation of gene expression. ASXL1 mutations are found in myeloproliferative neoplasms (MPN), myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML). They are generally associated with signs of aggressiveness and poor clinical outcome. Because of this, a systematic determination of ASXL1 mutational status in myeloid malignancies should help in prognosis assessment.

Domains

Cancer Hematology
Fichier principal
Vignette du fichier
1756-8722-5-12.pdf (259.23 Ko) Télécharger le fichier
1756-8722-5-12.xml (76.51 Ko) Télécharger le fichier
Origin : Publisher files allowed on an open archive
Format : Other
Loading...

Dates and versions

inserm-00698796 , version 1 (17-05-2012)

Identifiers

Cite

Véronique Gelsi-Boyer, Mandy Brecqueville, Raynier Devillier, Anne Murati, Marie-Joelle Mozziconacci, et al.. Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases.. Journal of Hematology and Oncology, 2012, 5 (1), pp.12. ⟨10.1186/1756-8722-5-12⟩. ⟨inserm-00698796⟩
133 View
209 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More